Medical Director, CHO
Hematology/Oncology Programs

Email: evichinsky@mail.cho.orgPhone: 510-428-3651

CHORI Staff Directory
CHORI Intranet
CHORI News

 

Publications

  1. 1. Singer ST, Vichinsky EP. Deferoxamine treatment during pregnancy: is it harmful? Amer J Hematol 1999;60:24-26.
  2. Waldron P, Pegelow C, Neumayr L, Haberken C, Earles A, Wesman R, Vichinsky E. Tonsillectomy, adenoidectomy and myringotomy in sickle cell disease: Perioperative morbidity. J Pediatr Hematol/Oncol 1999;21:129-135.
  3. Reed W, Jagust W, Al-Mateen M, Vichinsky E. The role of positron emission tomography indetermining the extent of CNS ischemia in patients with sickle cell disease. Amer J Hematol 1999;60:268-272.
  4. Vichinsky E, Rust D, Lubin B. A possible disparity between standard of care and delivery of care in sickle cell disease, as assessed from sickle cell centers. Intl J Pediatr Hematol/Oncol 1999;6:189-197.
  5. Harmatz P, Heyman MB, Cunningham J, Lee PDK, Styles L, Quirolo K, Kopp-Hoolihan L, Ghiron J, Hintz R, Vichinsky E. Effects of red blood cell transfusion on resting energy expenditure in adolescents with sickle cell anemia. J Ped Gastroenterol Nutr 1999;29:127-131.
  6. Morris C, Vichinsky E, Styles L. Clinician assessment for acute chest syndrome in febrile patients with sickle cell disease: Is it accurate enough? Ann Emerg Med 1999;34:64-69.
  7. Kinney TR, Sleeper LA, Vichinsky EP, and the Cooperative Study of Sickle Cell Disease. Silent cerebral infarcts in sickle cell anemia: a risk factor analysis. Pediatrics 1999;103:640-644.
  8. Kinney TR, Helms RW, Vichinsky E, et al. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial of the pediatric hydroxyurea group. Blood 1999;94:1550-1554.
  9. Vichinsky E, Neumayr L, Haberkern C, Eckman J, Koshy M, Black DM. The perioperative complication rate of orthopedic surgery in sickle cell disease: report of the National Sickle Cell Surgery Group. Amer J Hematol 1999;62:129-138.
  10. Hoppe C, Vichinsky E, Lewis B, Foote D, Styles L. Hydroxyurea and sodium phenylbutyrate therapy in thalassemia intermedia. Amer J Hematol 1999;62:221-227.
  11. Singer ST, Quirolo K, Nishi K, Hackney-Stephens E, Vichinsky E. Erythrocytapheresis for chronically transfused children with sickle cell disease: an effective method for maintaining a low Hemoglobin S level and reducing iron overload. J Clin Apheresis 1999;14:122-125.
  12. Singer ST, Vichinsky EP. Bone disease in beta-thalassemia major. Lancet 1999;354:881-2.
  13. Reed W, Vichinsky EP. Transfusion practice for sickle cell disease. Curr Opin Hematol 1999;6:432-436.
  14. Claster S, Vichinsky E. Acute chest syndrome in sickle cell disease: pathophysiology and management. J Intensive Care Med 1999;15:159-166.
  15. Kinney TR, Helms RW, O’Branski EE, Ohene-Frempong K, Wang W, Daeshner C, Vichinsky E, Redding-Lallinger R, Gee B, Platt OS, Ware RE for the Pediatric Hydroxyurea Group. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG KIDS Study, a Phase I/II trial. Blood 1999;94:1550-4.
  16. Vichinsky E, Rust D, Lubin B. A possible disparity between standard of care and delivery of care in sickle cell disease, as assessed from sickle cell centers. J Pediatr Hematol/Oncol 1999;6(3):189-197.
  17. Hagar W, Vichinsky E. Major changes in sickle cell disease. Adv Pediatr 2000; 47: 249-272.
  18. Walters MC, Storb R, Vichinsky E. Impact of bone marrow transplantation for symptomatic sickle cell disease: an interim report. Blood 2000;1918-1924.
  19. Reed W, Lorey F, Bojanowski J, Glass M, Lane P, Louie R. Lubin BH, Vichinsky E. Sickle cell anemia not diagnosed by newborn screening because of prior transfusion. J Pediatr 2000;136:248-50.
  20. Embury SH, Vichinsky EP. Sickle cell disease. In: Hematology: Basic Principles and Practices, Third Edition, Hoffman R, Benz EJ Jr., Shattil DJ, Furie B, Cohen HJ, Silberstein LE, McGlave PB, Eds. New York, Churchill Livingstone, 2000:510-554.
  21. Styles LA, Hoppe C, Klitz W, Vichinsky E, Lubin B, Theil E. Evidence for HLA-related susceptibility for stroke in children with sickle cell disease. Blood 2000;95:3562-3567.
  22. Vichinsky E, National Acute Chest Syndrome Study Group. Etiology and natural history of acute chest syndrome. N Engl J Med 2000;342:1855-65.
  23. Wang W, Gallagher D, Pegelow C, Wright E, Vichinsky E, Abboud M, Moser F, Adams R. Multicenter comparision of magnetic resonance imaging and transcrannial doppler ultrasonography in the evaluation of the central nervous system in children with sickle cell diease. J Pediatr Hematol/Oncol 2000;22:335-339.
  24. Harmatz P, Butensky E, Quirolo K, Williams R, Ferrell L, Moyer T, Golden D, Neumayr L, Vichinsky E. Severity of iron overload in patients with sickle cell disease receiving chronic red blood cell transfusion therapy. Blood 2000;96: 76-79.
  25. Vichinsky E. Contributor. U.S. newborn screening system guidelines II: follow-up of children, diagnosis, management, and evaluation. Statement of the council of regional networks for genetic services (CORN). J of Pediatr Oct 2000;137(4).
  26. Styles L, Aarsman A, Vichinsky E, Kuypers F. Secretory phospholipase A2 predicts impending acute chest syndrome in sickle cell disease. Blood 2000;96(9):3276-3278.
  27. Hoppe C, Vichinsky E, Quirolo K, Van Warmerdam J, Allen K, Styles L. Use of hydroxyurea in children 2 to 5 years with sickle cell disease. J Pediatr Hematol Oncol 2000;22(4):330-334.
  28. Vichinsky E. Guest editor. Transfusion-related iron overload in sickle cell anemia. Semin Hematol Nov 2000;38(4), Suppl 9.
  29. Vichinsky E. Current issues with blood transfusions in sickle cell disease. In: Semin Hematol Nov 2000;38(4), Suppl 9.
  30. Vichinsky E. Guest editor. Report of proceedings: 1999 international conference on E beta thalassemia. J Ped Hematol Oncol 22(6):550-572. 2000.
  31. Singer ST, Wu V, Vichinsky E. Alloimmunization and erythrocyte autoimmunization in transfusion dependent thalassemia patients of predominately Asian descent. Blood Nov 2000; 96(10):3369-3373.
  32. Reed W, Vichinsky EP. Sickle Cell Disease Anemia. In: Stockman JA, Lohr JA, eds. Essence of Office Pediatrics. Philadelphia, W.B. Saunders Company. 2001:378.
  33. Lo L Vichinsky E, Quirolo K. Thalassemia. In: Rakel and Bope, eds. Conn’s Current Therapy. W.B. Saunders Company. 2001:389-394.
  34. Morris C, Kuypers F, Larkin S, Sweeters N, Simon J, Vichinsky E, Styles L. Arginine therapy: a novel strategy to induce nitric oxide production in sickle cell disease. Br J Haematol Jul 2000;110:1-4.
  35. Morris CR, Kuypers F, Larkin S, Vichinsky E, Styles L. Patterns of arginine and nitric oxide in sickle cell disease patients with vaso-occlusive crisis and acute chest syndrome. J Pediatr Hematol/Oncol 2000;11:515-520.36. Singer TS, Wu V, Mignacca R, Kuypers F, Morel P, Vichinsky E. Alloimmunization and erythrocyte autoimmunization in transfusion-dependent thalassemia patients of predominately Asian descent. Blood 2000;22:539-542.
  36. Singer ST, Styles L, Bojanowski J, Quirolo K, Foote D, Vichinsky EP. The changing outcome of
    homozygous alpha-thalassemia: A cautious optimism. J Pediatr Hematol/Oncol
    2000;22(6):539-54.
  37. Fixler J, Vichinsky E, Walters M. Stem cell transplantation for sickle cell disease: can we reduce the toxicity? J of Pediatr Path and Molecular Med 2001;20:73-86.
  38. Reed W, Vichinsky EP. Transfusion therapy: a coming-of-age treatment for sickle cell disease. J Pediatr Hematol/Oncol 2001;23(4):197-202.
  39. Culberson D, Manci EA, Shah AK, Haynes J, Ballas SK, Pegelow C, Vichinsky E. Nesidioblastosis in sickle cell disease. J Ped Path Molecular Medicine 2000:20;155-165.
  40. Pegelow CH, Reed G, Moser F, Wang W, Bello J, Miller S, Vichinsky E, DeBaun M, Guarini L, Zimmerman R, Younkin D, Gallagher D. Natural history of silent infarct in children with sickle cell anemia (hbss). Accepted to Blood 200.
  41. Pegelow CH, Wang W, Granger S, Hsu L, Vichinsky E, Moser FG, Bello J, Zimmerman R, Adams RJ, Brambilla D. Silent infarct in children with sickle cell anemia and abnormal cerebral artery velocity. Accepted to Archives of Neurol.
  42. Jeng M, Feusner J, Vichinsky E. Central venous catheter complications in sickle cell disease. Accepted to Amer J Hematol.
  43. Cheung A, Harmatz P, Chen P, Larkin EC, Wun T, Barfield A, Adams R, Vichinsky E. Correlation of abnormal intracranial vessel velocity (measured by transcranial Doppler ultrasonography) with abnormal conjunctival vessel velocity (measured by computer-assisted intravital microscopy) in sickle cell disease. Accepted to Blood.
  44. Vichinsky E, Luban NLC, Wright E, Olivieri N, Driscoll C, Pegelow CH, Adams RJ, et al. Prospective red cell phenotype matching in stroke prevenion trial in sickle cell disease (STOP): a multicenter transfusion trial. Accepted to Transfusion.
  45. Wang WC, Wynn LW, Rogers ZR, Scott JP, Lane PA, Ware RE. A two-year pilot trial of hydroxyurea in very young children with sickle cell anemia. Accepted to J of Pediatr.
  46. Files, B, Adams R, Brambilla D, Kutlar A, Miller S, Vichinsky E, Wang W. Longitudinal changes in ferritin during chronic transfusion: a report from the Stroke Prevention Trial in Sickle Cell Anemia (STOP). Accepted to J Pediatr Hematol Onc.
  47. Treadwell M, Thomas E, Vichinsky E. Psychological, behavorial and social correlates of chronic pain syndrome in sickle cell disease. Accepted to Pain & Symptom Mgmt.
  48. Franck LS, Treadwell M, Jacob E, Vichinsky E. Assessment of sickle cell pain in children and young adults using the adolescent pediatric pain tool. Accepted to J Pain Symptom Mgmt.
  49. Harmatz P, Quirolo K, Singer T, Williams R, Ferrell L, Moyer T, Hackney-Stephens E, Golden D, Vichinsky E. Development of hemochromatosis in patients with sickle cell disease receiving chronic RBC transfusion therapy. In preparation.
  50. Lane P, Desposito F, Buchanan G, Pegelow C, Wethers D, Woods G, Vichinsky E. Health supervision for children with sickle cell disease. In preparation.
  51. Lo L, Vichinsky E. Pancytopenia induced by hypothermia. In preparation.
  52. Neumayr L, Dean D, Kelly D, Klemman K, Schachter J, Ballas S, Vichinsky E, and the Acute Chest Syndrome Study Group. Chlamydia pneumoniae and acute chest syndrome in patients with sickle cell anemia. In preparation.
  53. Aguilar C, Vichinsky E. Avascular necrosis. In preparation.
  54. Wang W, Riester K, Gallagher D, Thompson R, Guarini L, Vichinsky E, Wright E, Armstrong FD. Neuropsychometric performance in school-age children with sickle cell disease: a report from the Cooperative Study of Sickle Cell Disease. Submitted N Engl J Med.
  55. Hoppe C, Cheng S, Klitz W, Trachtenberg E, Erlich H, Vichinsky E, Styles L. A novel multilocus genotyping assay to identify genetic predictors of stroke in sickle cell anemia. Submitted to Blood.
  56. Lee Y, Kristovich K, Vichinsky E. Bone marrow transplantation in thalassemia: solving engraftment problems. Submitted to Biology of Blood and Marrow Transplantation.
  57. Lorey F, Cunningham G, Vichinsky E, Lubin B, Witkowska HE, Matsunaga A, Azimi M, Sherwin J, Eastman J, Farina F, Waye JS, Chui DHK. Population screening, molecular confirmation, and prevalence of hemoglobin H disease found in newborns in California. Submitted to New Engl J Med.
  58. Krishnamurti L, Blazar BR, Orchard P, Lubin BE, Abel S, Grossi M, Olston D, Vichinsky E, Wagner JE. Bone marrow transplantation without myeloablation for the treatment of sickle cell disease. Submitted to Blood.
  59. Silent infarct as a risk factor for overt stroke in children with sickle cell disease: a report from the cooperative study (CSSCD). Submitted to the New Engl J of Med.
  60. Vichinsky E. Transfusion therapy. Chapter submitted to NLBHI/NIH for publication in "Management and therapy of sickle cell disease".
  61. Nickerson BG, Browning I, Weiner S, Smithe JA, Wang W, Miller S, Wright L, Tapson V, Pegelow Ch, Ohene-Frempong K, Vichinsky E, and the Cooperative Study of Sickle Cell Disease. Pulmonary function in children with sickle cell disease, a report of the Cooperative Study of Sickle Cell Disease. Submitted to J Pediatr.
  62. Wang WC, Helms RW, Lynn H, Redding-Lallinger R, Gee B, Ohene-Frempong K, Smith-Whitney K, Vichinsky E, Styles L, Daeschner C, Platt O, Waclawiw M, Ware RE, Kinney TR. The effect of hydroxyurea on growth in children with sickle cell disease: results of the HUG-KIDS study. Submitted to J Pediatric.
  63. Hagar W, Vichinsky E, Theil E. Ferritin H/L subunit ration, H/L subunits, and iron in the liver of a child with neonatal hemochromatosis. Submitted to Intl J Pediatr Hematol/Oncol.
  64. Pegelow CH, Vichinsky E. Longitudinal changes in brain MRI findings in children with sickle cell disease. Submitted to Blood.



ABSTRACTS

  1. 1. Aguilar C, Neumayr L, Vichinsky E. Evaluation of hip function in sickle cell patients with avascular necrosis of the hip. 23rd Annual Meeting of the National Sickle Cell Disease Program, San Francisco, CA, March 6-9, 1999.
  2. Quirolo K, Hoffinger S, Aguilar C, Vichinsky E. Rotational osteotomy for the treatment of advanced avascular necrosis of the femoral head in sickle cell disease. 23rd Annual Meeting of the National Sickle Disease Program, San Francisco, CA, March 6-9, 1999.
  3. Treadwell M, Jacob E, Franck L, Vichinsky L, Ayo-Phillips L, Vichinsky E. Assessment of pain in pediatric patients with sickle cell disease using the adolescent pediatric pain tool. 23rd Annual Meeting of the National Sickle Cell Disease Program, San Francisco, CA, March 6-9, 1999.
  4. Wang W, Riester K, Gallagher D, Thompson R, Guarini L, Vichinsky E, Wright E, Armstrong FD. Progressive neurocognitive deficits occur in school-age children with sickle cell disease (SCD) in the absence of clinical or MRI evidence of infarction. 23rd Annual Meeting of the National Sickle Cell Disease Program, San Francisco, CA, March 6-9, 1999.
  5. Vichinsky E, The National Acute Chest Study Group. Acute chest syndrome associated with neurologic findings: An often fatal complication of sickle cell disease (SCD). 23rd Annual Meeting of the National Sickle Cell Disease Program, San Francisco, CA, March 6-9, 1999.
  6. Hoppe C, Van Warmerdam J, Allen K, Quirolo K, Vichinsky E, Styles L. The safety and efficacy hydroxyurea in 2 to 5 year old children with sickle cell disease. 23rd Annual Meeting of the National Sickle Cell Disease Program, San Francisco, CA, March 6-9, 1999.
  7. Morris C, Kuypers F, Larkin S, Kennedy N, Simon J, Vichinsky E, Styles L. Patterns of L-arginine and nitric oxide production in sickle cell disease and the effects of supplemental arginine therapy on nitric oxide production. 23rd Annual Meeting of the National Sickle Cell Disease Program, San Francisco, CA, March 6-9, 1999.
  8. Styles L, Larkin S, Kennedy, Simon J, Kuypers F, Vichinsky E. Low molecular weight heparin in sickle cell disease. 23rd Annual Meeting of the National Sickle Cell Disease Program, San Francisco, CA, March 6-9, 1999.
  9. Singer S, Quirolo K, Nishi K, Hackney E, Vichinsky E. Erythrocytapheresis in sickle cell patients: A safe and effective method for maintaining a low hemoglobin S level and reducing iron overload. 23rd Annual Meeting of the National Sickle Cell Disease Program, San Francisco, CA, March 6-9, 1999.
  10. Harmatz P, Quirolo Q, Singer T, Williams R, Farrell L, Moyer T, Hackney-Stephens E, Golden D, Vichinsky E. Development of hemochromatosis in patients with SCD receiving chronic RBC transfusion therapy. 23rd Annual Meeting of the National Sickle Cell Disease Program, San Francisco, CA, March 6-9, 1999.
  11. Gold JI, Treadwell M, Weissman L, Vichinsky E. Psychological adjustment in siblings of children with sickle cell disease: relationships with family and sibling adaptation processes. 23rd Annual Meeting of the National Sickle Cell Disease Program, San Francisco, CA, March 6-9, 1999.
  12. Treadwell M, Franck L, Edinburgh L, Ayo-Phillips L, Mayfield B, Vichinsky L, Quill L, Nichols R, van Warmerdam J, Vichinsky E. Improving developmentally appropriate pain assessment for pediatric patients with sickle cell disease. 23rd Annual Meeting of the National Sickle Cell Disease Program, San Francisco, CA, March 6-9, 1999.
  13. Hoppe C, Trachtenberg E, Klitz W, Vichinsky E, Lubin B, Styles L. HLA type as a predictor of stroke in children with sickle cell disease. 23rd Annual Meeting of the National Sickle Cell Disease Program, San Francisco, CA, March 6-9, 1999.
  14. Bojanowski J, Vichinsky E. Development of a group genetic counseling curriculum for young adults with sickle cell disease. 23rd Annual Meeting of the National Sickle Cell Disease Program, San Francisco, CA, March 6-9, 1999.
    15. Yamashita R, Russo P, Vichinsky E. Defining the social-economic parameters of comprehensive care for sickle cell disease: The Northern California Experience, 1990-1997. 23rd Annual Meeting of the National Sickle Cell Disease Program, San Francisco, CA, March 6-9, 1999.
  15. Vichinsky E, Luban N, Wright E, Olivieri N, Driscoll C, Pagelow C, Files B, Adams R, and the STOP investigators. Prospective red cell phenotype matching in STOP – A multicenter transfusion trial. 23rd Annual Meeting of the National Sickle Cell Disease Program, San Francisco, CA, March 6-9, 1999.
  16. Harmatz P, Butensky E, Quirolo K, Williams R, Ferrell L, Moyer T, Golden D, Neumayr L, Vichinsky E. Development of iron overload in patients with sickle cell disease receiving chronic red blood transfusion therapy. Annual Meeting of the American Society of Hematology, New Orleans, LA, December 3-7, 1999.
  17. Harmatz P, Butensky E, Ferrell L, Foote D, Hackney-Stevens E, Vichinsky E. Hepatic injury in hypertransfused patients with sickle cell disease or thalassemia. Annual Meeting of the American Society of Hematology, New Orleans, LA, December 3-7, 1999.
  18. Wu V, Singer TS, Mignacca R, Morel P, Vichinsky E. Alloimmunization and autoimmunization in predominantly asian transfusion dependent thalassemia patients. Annual Meeting of the American Society of Hematology, New Orleans, LA, December 3-7, 1999.
  19. Singer TS, Kuypers F, Mignacca R, Kennedy N, Olivieria N, Weatherall D, Vichinsky E. Hydroxyurea therapy in E-b-thalassemia: effect on hemoglobin and on RBCcharacteristics. Annual Meeting of the American Society of Hematology, New Orleans, LA, December 3-7, 1999.
  20. Olivieri NF, Sharma S, DeSilva S, Premawardena AP, Viens AM, Taylor CM, Symes KN, Vichinsky EP, Brittenham GM, Weatherall DJ. Impact of a low transfusion regimen on growth and iron loading in hemoglobin E-b-thalassemia. Annual Meeting of the American Society of Hematology, New Orleans, LA, December 3-7, 1999.
  21. Hoppe C, Cheng S, Klitz W, Trachtenberg E, Erlich H, Vichinsky E, Styles L. Multilocus evaluation of 60 potential genetic risk factors for stroke in sickle cell disease. Annual Meeting of the American Society of Hematology, New Orleans, LA, December 3-7, 1999.
  22. Claster S, Hammer M, Hagar W, Ataga K, Orringer E, Vichinsky E. Treatment of pulmonary hypertension in sickle cell disease with transfusion. Annual Meeting of the American Society of Hematology, New Orleans, LA, December 3-7, 1999.
  23. Hoppe C, Quirolo K, Vichinsky E, Van Warmerdam J, Allen K, Styles L. Hydroxyurea is safe and effective in 2 to 5 year old children with sickle cell disease. Annual Meeting of the American Society of Hematology, New Orleans, LA, December 3-7, 1999.
  24. Morris C, Kuypers F, Larkin S, Kennedy N, Simon J, Vichinsky E, Styles L. Oral arginine increases nitric oxide producton in patients with sickle cell disease during a vaso-occlusive crisis. Annual Meeting of the American Society of Hematology, New Orleans, LA, December 3-7, 1999.
  25. Styles L, Aarsman AJ, Larkin S, Vichinsky E, Kuypers F. Secretory phospholilpase A2 predicts impending acute chest syndrome in sickle cell disease. Annual Meeting of the American Society of Hematology, New Orleans, LA, December 3-7, 1999.
  26. Adams RJ, Brambilla D, McKie V, Files B, Vichinsky E, Abboud M, Hsu L, Pegelow C, Woods G, Miller S, Wang W, Olivieri N, Berman B, Hurlet A, Piomelli S, Driscoll C, Scher C, Wright E, Zimmerman R, Carl E, Nichols F, Kutlar A, Roach S, Granger S, Gallagher D, Adamkiewicz T. Risk of stroke in children with sickle cell disease and abnormal transcranial Doppler ultrasound. Annual Meeting of the American Society of Hematology, New Orleans, LA, December 3-7, 1999.
  27. Walters MC, Storb R, Patience M, Rogers ZR, Buchanan GR, Roberts I, Ogden A, Wiley JM, Kurtzberg J, Vichinsky E, Sullivan KM. Stable mixed chimerism after bone marrow transplantation for sickle cell disease. Annual Meeting of the American Society of Hematology, New Orleans, LA, December 3-7, 1999.
  28. Sharma S, Premawardena AP, Fathihu F, DeSilva S, DeSilva L, Vichinsky E, Weatherall DJ, Olivieri NF. Natural history study of hemoglobin E-beta thalassemia: the impact of splenectomy on growth and steady-state hemoglobin levels. Annual Meeting of the American Society of Hematology, New Orleans, LA, December 3-7, 1999.
  29. Styles L, Larkin S, Sweeters N, Simon J, Kuypers F, Vichinsky E. Abnormal response to low molecular weight heparin in sickle cell disease. Annual Meeting of the American Society of Hematology, New Orleans, LA, December 3-7, 1999.
  30. Kidd J, Witkowska E, Lubin B, Vichinsky E, Chui D, Trachtenberg E. Alpha thalassemia mutations detected by multiplex-pcr. Annual Meeting of the American Society of Hematology, New Orleans, LA, December 3-7, 1999.
  31. Walters MC, Storb R, Patience M, Rogers ZR, Buchanan GR, Roberts I, Ogden A, Wiley JM, Kurtzberg J, Vichinsky E, Sullivan KM. Stable mixed chimerism after bone marrow transplantation (BMT) for sickle cell disease (SCD). Annual Meeting of the American Society of Hematology, New Orleans, LA, December 3-7, 1999.
  32. Cheung ATW, Harmatz P, Chen PCY, Larkin EC, Wun T, Barfield A, Adams R, Vichinsky E. Correlation of abnormal intracranial vessel velocity with abnormal conjunctive vessel velocity in sickle cell disease. Annual Meeting of the American Society of Hematology, New Orleans, LA, December 3-7, 1999.
  33. Harmatz P, Moyer T, Butensky E, Quirolo K, Styles L, Williams R, Ferrell L, Vichinsky E. Variability in hepatic iron concentration from needle biopsy specimens in patients with SCD and secondary hemochromatosis. 24th Annual Meeting of the National Sickle Cell Disease Program, Philadelphia PA, April 9-12, 2000.
  34. Hoppe C, Trachtenberg E, Cheng S, Erlich H, Vichinsky E, Styles L. Genetic modifiers of leukocyte count in sickle cell disease. 24th Annual Meeting of the National Sickle Cell Disease Program, Philadelphia PA, April 9-12, 2000.
    36.
  35. Hoppe C, Cheng S, Klitz W, Trachtenberg E, Erlich H, Vichinsky E, Styles L. Simultaneous identification of genetic risk factors for stroke in sickle cell disease using a novel assay. 24th Annual Meeting of the National Sickle Cell Disease Program, Philadelphia PA, April 9-12, 2000.



  36. Morris C, Kuypers F, Larkin S, Kennedy N, Simon J, Vichinsky E, Styles L. Oral arginine: a novel strategy to induce nitric oxide production in sickle cell disease patients during a vaso-occlusive crisis. 24th Annual Meeting of the National Sickle Cell Disease Program, Philadelphia PA, April 9-12, 2000.
  37. Hagar R, Vichinsky E, Theil EC. Serrum ferritin, transfusion, liver ferritin and iron status in neonatal hemochromatosis. 28th World Congress of the International Society of Hematology, Toronto, Canada, August 26-30, 2000.
  38. Missov E, Mentzer W, Laprade M, Quill L, Sweeters N, Harmatz P, Vichinsky E, Pau B, Cann C, DeMarco T. Cardiac markers of injury in hemoglobinopathy patients with transfusion hemosiderosis. American Heart Association 2000.
  39. Hagar W, Vichinsky E, Theil E. Detection of three ferritin subunits (19,21, 23.5 kD) in human heart, liver, and spleen using 20% SDS-PAGE. American Society of Hematology 42nd Annual Meeting, San Francisco CA, December 1-5, 2000.
  40. Lorey FW, Eastman J, Lubin BH, Vichinsky EP, Farina F, Sherwin J, Finklesteing JZ, Waye JS, Chui DHK. Population screening, molecular confirmation, and prevalence of hemoglobin H disease among newborns in California. American Society of Hematology 42nd Annual Meeting, San Francisco CA, December 1-5, 2000.
  41. Krishnamurti L, Blazar B, Grossi M, Abel S, Lubin B, Vichinsky E. Successful use of non-myeloblative therapy in the treatment of severe hemoglobinopathies: proof of principle. American Society of Hematology 42nd Annual Meeting, San Francisco CA, December 1-5, 2000.
  42. Kutlar A, Harbin J, Jackson B, Holley L, Gallagher D, Clair B, Brambilla D, Adams R, McKie V, Hsu L, Files B, Vichinsky E, Pegelow C, Abboud M, Woods G, Olivieri N, Driscoll C, Miller S, Wang W, Piomelli S, Scher C, Berman B. Laboratory parameters in patients randomized in the STOP study and their modification by transfusion. American Society of Hematology 42nd Annual Meeting, San Francisco CA, December 1-5, 2000.
  43. Adams R, Brambilla D, McKie V, Files B, Vichinsky E, Abboud M, Hsu L, Pegelow C, Woods G, Miller S, Driscoll C, Scher C, Adamkiewicz T, Wright E, Zimmerman R, Carl E, Nichols F, Kutlar A, Roach S, Granger, Jones A, Gallagher D. Stroke prevention in sickle cell disease (STOP): final results. American Society of Hematology 42nd Annual Meeting, San Francisco CA, December 1-5, 2000.
  44. Hoppe C, Klitz W, Trachtenberg E, Cheng S, Grow M, Silbergleit A, Erlich H, dams R, Vichinsky E, Styles L. HLA and TNF apolymorphisms predict stroke risk in children with sickle cell anemia: confirmation from the stroke prevention trial (STOP). American Society of Hematology 42nd Annual Meeting, San Francisco CA, December 1-5, 2000.
  45. Harmatz P, Butensky E, Foote D, Hackney-Stevens E, Vichinsky E. Quantitative liver biopsy iron is poor indicator of toxicity risk in hypertransfused patients with sickle cell disease (SCD) or b thalassemia (BT). American Society of Hematology 42nd Annual Meeting, San Francisco CA, December 1-5, 2000.
  46. Olivieri N, Brambilla D, McKie V, Piomelli S, Kutlar A, Files B, Berman B, Driscoll C, Adamkiewicz T, Zimmerman R, Carl E, Roach , Hsu L, Wang W, Vichinsky E, Abboud M, Pegelow C, Granger S, Gallagher D, Adams R. Changes in cerebral blood flow velocities during chronic transfusion therapy to prevent stroke in sickle cell disease. American Society of Hematology 42nd Annual Meeting, San Francisco CA, December 1-5, 2000.
  47. Morris C, Hagar W, van Warmerdam J, Kuypers FA, Larkin S, Claster S, Vichinsky E. Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease? American Society of Hematology 42nd Annual Meeting, San Francisco CA, December 1-5, 2000.
  48. Singer ST, Kuypers FA, Mignacca R, Coates T, Olivieri N, Weatherall D, Vichinsky E. Impact of hydroxyurea (HU) treatment on erythropoiesis and RBC characteristics in E b thalassemia patients. American Society of Hematology 42nd Annual Meeting, San Francisco CA, December 1-5, 2000.

 

© 2005 Children's Hospital Oakland Research Institute
5700 Martin Luther King Jr Way • Oakland, California 94609
Phone 510-450-7600 • Fax 510-450-7910
Site MapDisclaimer